Platelet inhibition by low-dose aspirin is not influenced by body mass or weight

References

• Heffron SP, Parham J, Pendse J, Aleman JO. Treatment of obesity in mitigating metabolic risk. Circ Res 2020;126:1646–1665. doi:10.1161/CIRCRESAHA.119.315897.
   PubMed Web of Science ®Google Scholar
• Sankaralingam S, Kim RB, Padwal RS. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. Can J Cardiol 2015;31:167–176.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet (London, England) 2018;392:387–399.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–1372.
   PubMed Web of Science ®Google Scholar
• Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, Cox D. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–2325.
   PubMed Web of Science ®Google Scholar
• Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:2153–2158.
   PubMed Web of Science ®Google Scholar
• Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–1263.
   PubMed Web of Science ®Google Scholar
• Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, Boutaud O, Oates JA. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension (Dallas, Tex: 1979) 2012;59:719–725.
   PubMed Web of Science ®Google Scholar
• Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PloS one 2015;10:e0126767.
   PubMed Web of Science ®Google Scholar
• Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, Becker DM. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 2010;13:56–62. doi:10.1111/j.1751-7141.2009.00058.x.
   PubMedGoogle Scholar
• Norgard NB. Obesity and altered aspirin pharmacology. Clin Pharmacokinet 2018;57:663–672. doi:10.1007/s40262-017-0611-8.
   PubMed Web of Science ®Google Scholar
• Pace S, Sautebin L, Werz O. Sex-biased eicosanoid biology: impact for sex differences in inflammation and consequences for pharmacotherapy. Biochem Pharmacol 2017;145:1–11. doi:10.1016/j.bcp.2017.06.128.
   PubMed Web of Science ®Google Scholar
• DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014–3019. doi:10.2337/db07-0707.
   PubMed Web of Science ®Google Scholar
• Allen N, Barrett TJ, Guo Y, Nardi M, Ramkhelawon B, Rockman CB, Hochman JS, Berger JS. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis 2019;282:11–18. doi:10.1016/j.atherosclerosis.2018.12.029.
   PubMed Web of Science ®Google Scholar
• Friede KA, Infeld MM, Tan RS, Knickerbocker HJ, Myers RA, Dubois LG, Thompson JW, Kaddurah-Daouk R, Ginsburg GS, Ortel TL, et al. Influence of sex on platelet reactivity in response to aspirin. J Am Heart Assoc 2020;9:e014726. doi:10.1161/JAHA.119.014726.
   PubMed Web of Science ®Google Scholar
• Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS. Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets 2014;25:188–192. doi:10.3109/09537104.2013.793794.
   PubMed Web of Science ®Google Scholar
• Merolla M, Nardi MA, Berger JS. Centrifugation speed affects light transmission aggregometry. Int J Lab Hematol 2012;34:81–85. doi:10.1111/j.1751-553X.2011.01360.x.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2016;164:836–845. doi:10.7326/M16-0577.
   PubMed Web of Science ®Google Scholar
• Petrucci G, Zaccardi F, Giaretta A, Cavalca V, Capristo E, Cardillo C, Pitocco D, Porro B, Schinzari F, Toffolo G, et al. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. J Thromb Haemost 2019;17:885–895. doi:10.1111/jth.14445.
   PubMed Web of Science ®Google Scholar
• Lee S, Eichelberger B, Kopp CW, Panzer S, Gremmel T. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. Vascul Pharmacol 136 2021;106819. doi:10.1016/j.vph.2020.106819.
   PubMed Web of Science ®Google Scholar
• Heffron SP, Marier C, Parikh M, Fisher EA, Berger JS. Severe obesity and bariatric surgery alter the platelet mRNA profile. Platelets 2019;30:967–974.
   PubMed Web of Science ®Google Scholar
• Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014;510:92–101.
   PubMed Web of Science ®Google Scholar
• Kain V, Liu F, Kozlovskaya V, Ingle KA, Bolisetty S, Agarwal A, Khedkar S, Prabhu SD, Kharlampieva E, Halade GV. Resolution agonist 15-epi-Lipoxin A(4) programs early activation of resolving phase in post-myocardial infarction healing. Sci Rep 2017;7:9999.
   PubMedGoogle Scholar
• Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E(-/-) mice. Br J Pharmacol 2017;174:4043–4054.
   PubMed Web of Science ®Google Scholar
• Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J 2016;30:2792–2801.
   PubMed Web of Science ®Google Scholar
• Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 2010;177:2116–2123.
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B. Type 2 diabetes, obesity, and aspirin responsiveness. J Am Coll Cardiol 2017;69:613–615.
   PubMed Web of Science ®Google Scholar
• Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J 2018;39:1672–1686f.
   PubMed Web of Science ®Google Scholar
• Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, Hadamitzky M, Schunkert H, Laugwitz KL, Massberg S, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets 2015;26:53–58.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res 2013;161:421–429.
   PubMed Web of Science ®Google Scholar
• Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:1511–1515.
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007;100:203–205.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Atherosclerosis 2015;240:439–445.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011;128:352–357.
   PubMed Web of Science ®Google Scholar
• Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001–1005.
   PubMed Web of Science ®Google Scholar